[Ip-health] New heat-stable drug to prevent maternal mortality

Tabitha Ha Tabitha.Ha at oxfam.org
Fri Aug 17 02:02:56 PDT 2018


At the end of June, Ferring Pharmaceutical announced the result of the clinical trials which demonstrated that heat stable carbetocin was as useful as oxitocyn in prevent bleeding after childbirth. Since carbetocin is heat stable -which oxitocyn isn't it-  will be a huge advantage in LIMC. Around 14 million women globally suffer from Postpartum hemorrhaging each year, and 70,000 women die as a result.

The clinical trials have been developed by the WHO and funded by MSD for Mothers( Merck Foundation). As part of the agreement, WHO, MSD and Ferring Pharmaceuticals agree to sell carbetocin at the lowest price possible in LIC and some middle income countries.

In this New England Journa<https://www.nejm.org/doi/pdf/10.1056/NEJMoa1805489>l there is a mention of the access agreement on page 2. It says 'If noninferior to oxytocin, the heat-stable formulation of carbetocin would be made available in public-sector facilities of high-burden countries at an affordable and sustainable price, according to a memorandum of understanding signed by representatives of the WHO, Ferring Pharmaceuticals, and Merck.'

Here are a couple further articles

Tabitha Ha  | Advocacy and Campaigns Officer - Access to medicines | Even It Up campaign
Oxfam International | based in London, UK (UTC +1)
Email: tabitha.ha at oxfam.org<mailto:tabitha.ha at oxfam.org> | Skype: Tabitha.ha | Twitter: @tabithaha

More information about the Ip-health mailing list